Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in…
If I still need help sleeping after a few weeks on zolpidem, what's the plan — stop, switch to a drug with better long-term evidence, or add non-drug treatment like CBT-I?
Well-supported by good-quality research. how we score evidence
Caveat on this rating: Co-funded in part by Angelini Pharma alongside public funders (NIHR Oxford Health BRC, MRC, Swiss NSF); registration status could not be read from the paywalled full text.
In a network meta-analysis of 154 double-blind randomized trials (44,089 people), zolpidem and similar drugs improved sleep in the short term, but eszopiclone and lemborexant showed the most favorable balance of benefit and tolerability for longer-term treatment, and long-term data for zolpidem were limited.
Worth asking
If I still need help sleeping after a few weeks on zolpidem, what's the plan — stop, switch to a drug with better long-term evidence, or add non-drug treatment like CBT-I?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Short-term treatment of insomnia characterized by difficulties with sleep initiation
Source
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis — De Crescenzo F, et al. (2022)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1016/S0140-6736(22)00878-9
DOI: 10.1016/S0140-6736(22)00878-9
How this was scored
- Study design
- Meta-analysis of randomised trials
- Funding
- Mixed public and industry funding
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 44,089
- Preregistered
- No
- Conflicts disclosed
- No
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "strong evidence". Well-supported by good-quality research. It scores 75 out of 100 on our published rubric. One caveat travels with that badge: Co-funded in part by Angelini Pharma alongside public funders (NIHR Oxford Health BRC, MRC, Swiss NSF); registration status could not be read from the paywalled full text. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis — De Crescenzo F, et al. (2022). Published in: Top-tier peer-reviewed journal. DOI: 10.1016/S0140-6736(22)00878-9. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Meta-analysis of randomised trials. Funding: Mixed public and industry funding. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is zolpidem (Ambien, Edluar, Intermezzo), ambien, edluar, intermezzo FDA approved?
Yes — FDA approved for Short-term treatment of insomnia characterized by difficulties with sleep initiation. Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.